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NEXT GEN CAR T CELLS 
 
Michael C. Jensen, MD 
Janet & Jim Sinegal Endowed Professor of Pediatrics, Adjunct Professor of Bioengineering, University of 
Washington School of Medicine 
Director, Ben Towne Center for Childhood Cancer Research, Seattle Children's Research Institute 




Recent conceptual as well as technological advances in the areas of molecular immunology, gene 
transfer, and cell processing have fostered increasingly sophisticated translational applications of 
adoptive T cell therapy for oncologic disease employing genetically-modified T-lymphocytes. My 
laboratory’s work focuses on T-cell genetic modification for re-directing antigen specificity to tumors 
utilizing recent advances not only in the composition and specificity of receptor antigen recognition 
domains, but also the evolution of multifunctional cytoplasmic signaling domains developed for these 
chimeric antigen receptors (CARs) that provide dual activation and co-stimulatory signaling. My group is 
also investigating the context of adoptive transfer with respect to the conditioning of the recipient for 
enhanced T-cell engraftment and expansion, the grafting of CARs on to central memory T-cells having 
endogenous TCR specificities for viral epitopes to which the host has robust immunity, and, the provision 
tumor microenvironment survival capabilities. The increasingly broad array of genetic manipulations 
including not only transgene insertion, but targeted gene knock out using engineered targeted nucleases 
such as TALEN’s and ZFN, as well as expression regulatory constructs provides for the creation of 
synthetic biology of orthogonal immune responses based on gene modified T cell adoptive transfer. The 
next decade of advances in this arena will depend on iterative bench-to-bedside back-to-the-bench 
translational studies capable of sustaining the evolution of these technologies in the context of clinical 
parameters relevant to the pediatric oncology patient population. 
 
